Researchers from Canada randomly assigned adults with C. diff infections to receive frozen or fresh FMT via enema. Thirteen weeks after treatment, 83.5 percent of the frozen FMT group and 85 percent of the fresh FMT group had clinical resolution of diarrhea without relapse.
“In this clinical trial, the use of frozen FMT compared with fresh FMT for the treatment of recurrent or refractory CDI was noninferior in terms of efficacy; findings for frozen FMT and fresh FMT were similar in terms of safety,” the study authors wrote. “Given the potential advantages of providing frozen FMT, its use is a reasonable option in this setting.”
More articles on C. diff:
Predictive preventive model reduces C. diff cases in ICU: 3 study findings
Research highlights how antibiotics enable C. diff infections
Mayo Clinic reduces C. diff infections 30% using UV light disinfection
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.